CASE AND COMMENTARY: PEER-REVIEWS ARTICLE
Should BMI Help Determine Gender-Affirming Surgery Candidacy?
Elijah Castle, Laura Kimberly, PhD, MSW, MBE, Gaines Blasdel, Augustus Parker, Rachel Bluebond-Langner, MD, and Lee C. Zhao, MD, MS

Abstract
Use of body mass index (BMI) as a health care metric is controversial, especially in candidacy assessments for gender-affirming surgery. When considering experiences of fat trans individuals, it is important to advocate for equitable divisions of responsibility for and recognition of systemic fat phobia. This commentary on a case suggests strategies for increasing equitable access to safe surgery for all body types. If surgeons use BMI thresholds, simultaneous effort must be made to advocate for data collection so that surgical candidacy criteria are evidence-based and equitably applied.

The American Medical Association designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™ available through the AMA Ed Hub™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case
ZZ is a trans man and a patient of Dr S, a surgeon at a clinic offering gender-affirming services, including hormone therapy, chest surgeries, and genital surgeries. During 5 years of hormone treatment, ZZ’s weight increased to a point at which he now has a BMI of 35, which is clinically considered class II obesity.1 As a result, he does not qualify for most gender-affirming surgeries (GAS) offered by Dr S at the clinic. ZZ is distressed and asks, “What was the point of hormone therapy if all it did was make me so fat I can’t get surgery?”

Dr S considers how to respond.

Commentary
Transgender, nonbinary, and other non-cisgender (henceforth referred to as trans) individuals with a body mass index (BMI) of at least 30 (referred to clinically as “obesity”),1 could be denied access to GAS2 due to systemic bias and social inequity. High BMI is associated with conditions such as sleep apnea,3,4,5 type 2 diabetes, gallbladder disease, and certain types of cancers.6 It is also associated with perioperative issues, including surgical site infection,7 increased operative time,8 and greater technical difficulty when operating9,10 and hence is often a primary factor in GAS candidacy.9 However, this risk metric can obscure other multifactorial causes11,12,13 that
contribute to poor surgical outcomes. Moreover, some consider BMI thresholds to
be a manifestation of weight stigma, or the negative stereotyping of and
discrimination against fat individuals. (We use the word fat here as a neutral
descriptor of body size in alignment with fat activists to help destigmatize the word.)
Weight stigma, among other biases, can cause clinicians to erroneously attribute a
patient’s health issues to their body size. As a result of weight stigma, fat patients may
be inclined to avoid clinical care.

Equitable treatment requires that we consider the current surgical risks for fat patients,
how weight stigma contributes to these risks, and the appropriate uses of BMI in
clinical care. It is also important to acknowledge the problematic history of BMI,
including the lack of validation for its use in non-cisgender populations of color and the
relationship between weight stigma and racism. For example, among Black men,
experience of major discrimination is associated with obesity.

Here, we discuss weight stigma, inadequate empirical evidence of GAS risks associated
with BMI, and how to reduce barriers to GAS for fat trans people like ZZ by addressing
structural oppression. In the absence of definitive evidence of a direct causal link
between high BMI and poor GAS outcomes, we propose a more holistic approach to
surgical candidacy that includes shared decision making, wherein BMI is not used as the
sole determinant of GAS access but is considered alongside weight stigma and factors
like procedure type and body composition.

Weight Stigma
ZZ’s weight and his perception of how it affects his surgery access is mediated by
internalized weight stigma. Internalized weight stigma poses concrete risks to patients
by negatively influencing eating and exercise behavior, and it is also associated with
depression and body shame. Even if ZZ ends up having surgery, he may struggle to
find peer support, the benefits of which for surgery and medical care have been
described in the existing literature for fat trans people who do not have easy access to
GAS.

Fat patients may also experience a lower quality of care due to clinician biases.
Surgical teams can limit reinforcing these biases in clinical environments by questioning
their own anti-fat attitudes, as well as by educating clinicians and staff members on the
complexity of weight and weight change. Quality of care can be improved by using
motivational interviewing and patient-centered communication and by shifting the
focus from weight loss to the benefits of behavior changes, such as increased physical
activity.

Known and Anticipated Risks and Benefits
The benefits of GAS, including decreased gender incongruence, improved quality of life,
and decreased suicide risk, cannot be understated. These data help make the case
for proceeding with surgery despite potential risks associated with an elevated BMI.

Existing data on GAS indicate that the risk of complications is contingent on multiple
factors, including procedure type, BMI, and body composition. Two studies have
reported that gender-affirming mastectomy for patients with a BMI of 30 to 39.9 is
relatively safe. Data on complication risk specific to genital GAS, however, is
lacking and, with few exceptions, is not available for those above a BMI of 30 (see
Tables 1 and 2).
# Table 1. Stratifying Complications in Gender-Affirming Mastectomies, Including for People With a Body Mass Index of at Least 30

<table>
<thead>
<tr>
<th>Author, y</th>
<th>Max BMI</th>
<th>Common complications reported, No. (%)</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berry (2012)</td>
<td>NR</td>
<td>All, 100</td>
<td>6 (6.0)</td>
</tr>
<tr>
<td>Frederick (2017)</td>
<td>41.3</td>
<td>All, 88</td>
<td>8 (9.1)</td>
</tr>
<tr>
<td>Donato (2017)</td>
<td>NR</td>
<td>All, 130</td>
<td>18 (13.8)</td>
</tr>
<tr>
<td>McEvenue (2017)</td>
<td>NR</td>
<td>All, 679</td>
<td>44 (6.5)</td>
</tr>
<tr>
<td>Kääriäinen (2017)</td>
<td>NR</td>
<td>All, 57</td>
<td>14 (24.6)</td>
</tr>
<tr>
<td>van de Grift (2017)</td>
<td>35</td>
<td>All, 54</td>
<td>16 (29.6)</td>
</tr>
<tr>
<td>Knox (2017)</td>
<td>40</td>
<td>All, 101</td>
<td>12 (11.9)</td>
</tr>
<tr>
<td>Gallagher (2019)</td>
<td>57</td>
<td>All, 153</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Watanabe (2019)</td>
<td>NR</td>
<td>All, 358</td>
<td>15 (4.2)</td>
</tr>
<tr>
<td>Stein (2020)</td>
<td>≥ 40</td>
<td>All, 97</td>
<td>1 (1.0)</td>
</tr>
<tr>
<td>Pittelkow (2020)</td>
<td>NR</td>
<td>All, 145</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Rothenberg (2021)</td>
<td>≥ 50</td>
<td>All, 948</td>
<td>44 (4.6)</td>
</tr>
<tr>
<td>Naides (2021)</td>
<td>46.8</td>
<td>All, 72</td>
<td>4 (5.6)</td>
</tr>
<tr>
<td>Rifkin (2022)</td>
<td>NR</td>
<td>All, 486</td>
<td>25 (5.1)</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; NR, not reported; SWD, surgical wound dehiscence.

* Specific value not reported.
Table 2. Stratifying Complications in Other Gender-Affirming Surgeries, Including for People With a Body Mass Index of at Least 30

<table>
<thead>
<tr>
<th>Author, y</th>
<th>Max. BMI</th>
<th>Vaginoplasty</th>
<th>Common complications reported, No. (%)</th>
<th>Metoidioplasty</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gaither (2018)</td>
<td>NR</td>
<td>All, 330</td>
<td>Vaginal fistula or wound</td>
<td>Infection</td>
<td>SWD</td>
</tr>
<tr>
<td>Ives (2019)</td>
<td>48.2</td>
<td>All, 101</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 30, 27</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginoplasty</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phalloplasty</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascha (2017)</td>
<td>NR</td>
<td>All, 213</td>
<td>Urethral complications</td>
<td>Partial or total flap necrosis/loss</td>
<td>SWD</td>
</tr>
<tr>
<td>Wirthmann (2018)</td>
<td>44.1</td>
<td>All, 32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 30, NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Watanabe (2021)</td>
<td>31</td>
<td>All, 32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 30, NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spennato (2022)</td>
<td>37.5</td>
<td>All, 45</td>
<td>Fistula: 39 (86.7)</td>
<td>Stricture: 19 (42.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 30, NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoidioplasty</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bordas (2021)</td>
<td>32.8</td>
<td>All, 813</td>
<td>Urethral complications</td>
<td>Infection</td>
<td>SWD</td>
</tr>
<tr>
<td></td>
<td>≥ 30, NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; NR, not reported; RFF, radial forearm flap; SWD, surgical wound dehiscence.

a Patient experienced total flap loss and subsequently underwent a second successful RFF phalloplasty.

b Including rectovaginal and vesicovaginal fistulas, as well as intraoperative rectal/bladder injury.
In this data’s absence we can extrapolate from similar procedures.\textsuperscript{9} For example, in robot-assisted laparoscopic radical prostatectomy, BMI correlates with pelvic visceral fat volume, pelvic width, and working space.\textsuperscript{43} More pelvic visceral fat can increase operative time and incidence of complications.\textsuperscript{43} However, in colorectal surgery, BMI appears to be less accurate at predicting the amount of visceral fat.\textsuperscript{44} Overall body composition therefore may be more helpful when estimating surgical risk, as BMI does not account for the effects of body composition on surgical outcomes. Reporting on surgical complications is also not standardized (see Tables 1 and 2).

Complications stratified by BMI provide more specific information on potential risks and outcomes, although only the studies by Stein et al\textsuperscript{34} and Gallagher et al\textsuperscript{32} analyze the data in this way. For gender-affirming mastectomy, a BMI of 30 or more is associated with hematoma,\textsuperscript{22,23,32,34} seroma,\textsuperscript{22,34,45} infection,\textsuperscript{22,32,34,36} and wound dehiscence.\textsuperscript{32,34,36} For phalloplasty, one study found no statistically significant relationship between a BMI of at least 25 and increased complications,\textsuperscript{25} although results may vary with type of reconstruction. In another study, one patient with a BMI of 44.1 experienced total flap loss and underwent a second successful phalloplasty, although this patient engaged in heavy smoking,\textsuperscript{39} a known risk factor for impaired wound healing independent of BMI.\textsuperscript{46} Ascha et al found that patients undergoing radial forearm flap phalloplasty experienced fewer complications and had a higher BMI than patients undergoing anterolateral thigh flap phalloplasty.\textsuperscript{38} However, Wirthmann et al showed that there was a trend (though not significant) toward complications for patients with a BMI greater than 25 undergoing radial forearm flap phalloplasty.\textsuperscript{39} Watanabe et al suggested that BMI can be useful, in tandem with radiographic imaging, when selecting type of donor flap to use for penile creation in phalloplasty.\textsuperscript{33} Similarly, for vaginoplasty, data on complications stratified by BMI are limited,\textsuperscript{24} and the existing data are too sparse to lead to definitive conclusions about the use of BMI in assessing surgical candidacy.

Risks for patients with a higher BMI precede the operating table, such as the risks accompanying weight loss attempts to qualify for surgery. Losing weight safely or sustainably is difficult and often not achievable for most patients recommended to pursue weight loss.\textsuperscript{47} It can even be harmful for some individuals to attempt any weight changes, especially those with an active or previous eating disorder, which is characteristic of a large portion of trans individuals.\textsuperscript{48,49} Additionally, permanent weight loss attempts often result in cycles of weight loss and regain, which are ineffective and have their own health risks.\textsuperscript{50}

We must consider the ethics of recommending that patients pursue medical or surgical interventions for weight loss before undergoing GAS without evidence that weight loss will significantly affect surgical outcomes as well as long-term outcomes in cases in which patients lose weight preoperatively and then experience postoperative weight regain. Lastly, some fat individuals regard their body size as part of their identity\textsuperscript{16,51} and do not want to attempt any kind of weight change. Recommending weight loss to fat individuals whose trans identities incur significant social criticism can similarly be perceived as a negative judgment and thereby damage the patient-surgeon relationship.

**Shared Decision Making**

In the absence of ample data, shared decision making supports informed consent. Increased risk of complications is often used to rationalize denying surgery to fat patients, as surgeons operating on individuals who may be at higher risk of complications could be accused of poor judgment or even face litigation if problems
arise intraoperatively.\textsuperscript{52,53} Creating a more equitable division of decision-making responsibility between patients and surgeons can mitigate surgeons’ fears of performing unsafe surgeries or patients’ fears of experiencing poor outcomes. This goal can be achieved by proper informed consent through patient education and by allowing patients to be involved in the final decision.

Fear of litigation does not adequately justify refusal to operate, especially if the complications are manageable through wound care or revision surgeries. Even data on serious complications, like total flap loss, can help set patient expectations and possibly reduce legal action stemming from miscommunication. A paradigm of robust informed consent and collaboration encourages patient autonomy and strengthens patient-surgeon relationships.

**Equitable Access to Surgery**

Evidence regarding causes of fatness increasingly points toward macro-structural factors,\textsuperscript{54} which, alongside structural stigma, contribute to health inequalities.\textsuperscript{55,56} In the case of other stigmatized characteristics, such as race, attempts to address stigma aim to remove its effects on the patient rather than remove the characteristic itself. Thus, if it is assumed that people will continue to have diverse body sizes, solutions should be sought that will allow surgeons to safely operate on individuals of all sizes, including fat individuals.

We recognize that, in addition to explicit, intentional BMI thresholds, de facto BMI thresholds for surgery also exist,\textsuperscript{9} which include technical difficulties and equipment limitations. We hope these barriers to care can be resolved through innovation and investment in equipment, such as operating tables and longer tools suited for patients at high weights or with more tissue.\textsuperscript{57} Bariatric surgery specialists can model learning proper techniques and using equipment for safer operations.\textsuperscript{57} Examples from colorectal surgery include alternative incision sites and use of prophylactic mesh when there is more visceral fat.\textsuperscript{44} Preoperative radiographic imaging for flap surgeries, such as phalloplasty, can inform procedure decision making and planning.\textsuperscript{7,58,59} BMI can also be used to identify cases appropriate for less experienced surgeons.\textsuperscript{43}

Access to GAS for fat trans people will not improve if BMI thresholds continue to bar patients from care without critical consideration of their use. BMI lacks the nuance to fully inform surgical candidacy. While still acknowledging the discriminatory origins of BMI, we believe its usefulness remains due to its ubiquity in the existing surgical outcomes literature. In a vacuum where no weight stigma exists, BMI is a helpful metric for data collection and procedural decision making, as well as for innovation of novel solutions in surgery for fat individuals. The problem is that BMI can enable and reinforce weight stigma, and that is what we must avoid. When assessing surgical candidacy, the risks associated with high BMI must be weighed against the benefits of GAS, which can be life-changing and sometimes even lifesaving.

**References**


Elijah Castle is an associate research coordinator in the Department of Urology at New York University Langone Health and is pursuing a master’s degree in bioethics at the New York University School of Global Public Health in New York City. He works in patient-centered research, addressing topics such as patient-clinician relationships, knowledge dissemination and health education, the impacts of weight stigma on provisions of care, gender-affirming care for trans youth and adolescents, and patient-reported outcomes in gender-affirming surgery.

Laura Kimberly, PhD, MSW, MBE is an assistant professor in the Hansjörg Wyss Department of Plastic Surgery and the Department of Population Health at the New York University Grossman School of Medicine in New York City. Her research examines ethical and psychosocial considerations in gender-affirming care, including centering patients’ lived experiences of embodied identity over the life course.

Gaines Blasdel is a second-year medical student at the University of Michigan Medical School in Ann Arbor. He has conducted gender-affirming surgery research in the Department of Urology at New York University Langone Health and previously worked directly with transgender youth and young people living with HIV at the Callen-Lorde Community Health Center adolescent clinic, where he also developed gender-affirming surgery resources and programs. His academic interests include patient-centered outcomes research in gender-affirming surgery.

Augustus Parker is a third-year medical student at the New York University (NYU) Grossman School of Medicine in New York City. He will begin his plastic surgery
residency at NYU in 2023. His academic interests include surgical innovation and patient-reported outcomes research in gender-affirming surgery.

Rachel Bluebond-Langner, MD is the Laura and Isaac Perlmutter Associate Professor of Reconstructive Plastic Surgery in the Hansjörg Wyss Department of Plastic Surgery at the New York University (NYU) Grossman School of Medicine in New York City. She also serves as co-director of transgender surgery services at NYU and is an associate editor of Plastic and Reconstructive Surgery. She performs the full spectrum of gender-affirming genital and chest surgeries in a multidisciplinary setting in addition to gender-affirming surgery outcomes research.

Lee C. Zhao, MD, MS is a reconstructive urologist and a co-director of the Transgender Reconstructive Surgery Program at New York University Langone Health in New York City. He performs primary and revision gender-affirming surgery as part of a multidisciplinary team. He also serves as an associate editor of the Journal of Sexual Medicine and was a coauthor of the American Urologic Association core curriculum on gender-affirming surgery and guidelines on male urethral stricture.

Editor’s Note
The case to which this commentary is a response was developed by the editorial staff.

Citation
AMA J Ethics. 2023;25(7):E496-506.

DOI
10.1001/amajethics.2023.496.

Conflict of Interest Disclosure
The author(s) had no conflicts of interest to disclose.

The people and events in this case are fictional. Resemblance to real events or to names of people, living or dead, is entirely coincidental. The viewpoints expressed in this article are those of the author(s) and do not necessarily reflect the views and policies of the AMA.